Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2007-003703-13
    Sponsor's Protocol Code Number:CQAB149B2305
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2007-10-26
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2007-003703-13
    A.3Full title of the trial
    Estudio cruzado, fase III, multicéntrico, aleatorizado, doble ciego, doble enmascarado, controlado con placebo, con 4 tratamientos y 3 periodos de bloques incompletos para evaluar la eficacia y seguridad de indacaterol 300 µg o.d administrado por la noche en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) de moderada a grave, utilizando salmeterol 50 µg b.i.d. como control activo
    A.4.1Sponsor's protocol code numberCQAB149B2305
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNovartis Farmacéutica S.A.
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameIndacaterol
    D.3.2Product code QAB149
    D.3.4Pharmaceutical form Inhalation powder, hard capsule
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPInhalation use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIndacaterol
    D.3.9.2Current sponsor codeQAB149
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number300
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Serevent Accuhaler
    D.2.1.1.2Name of the Marketing Authorisation holderGlaxo Wellcome UK Ltd
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Inhalation powder
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPInhalation use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNsalmeterol
    D.3.9.1CAS number 89365-50-4
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboInhalation powder, hard capsule
    D.8.4Route of administration of the placeboInhalation use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboInhalation powder
    D.8.4Route of administration of the placeboInhalation use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Enfermedad Pulmonar Obstructiva Crónica (EPOC)
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 9.1
    E.1.2Level LLT
    E.1.2Classification code 10010952
    E.1.2Term COPD
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    •Administración nocturna de indacaterol frente a placebo
    Evaluar la eficacia de indacaterol 300 µg o.d. cuando se administra por la noche en comparación con placebo en pacientes con EPOC de moderada a grave, evaluada mediante FEV1 valle a las 23 h 10 min. y a las 23 h 45 min. postdosis tomada el día 14
    E.2.2Secondary objectives of the trial
    •Seguridad: Evaluar la seguridad de indacaterol 300 µg administrado por la noche por lo que se refiere a ECG, analíticas de laboratorio, presión arterial, frecuencia cardiaca y acontecimientos adversos.

    •Administración matutina y nocturna de indacaterol frente a placebo después de 14 días de tratamiento: Comparar de modo descriptivo el FEV1 valle de indacaterol 300 µg o.d. cuando se administra por la mañana frente a placebo con el FEV1 valle cuando se administra por la noche frente a placebo en pacientes con EPOC de moderada a grave.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1.Hombres y mujeres adultos de edad  40 años, que hayan firmado el formulario de consentimiento informado antes de iniciar cualquier procedimiento relacionado con el estudio.
    2.Pacientes ambulatorios cooperadores con un diagnóstico de EPOC (de moderada a grave de acuerdo con las Guías GOLD, 2006) y:
    a)Antecedentes de consumo de tabaco de al menos 20 paquetes al año
    b)FEV1 postbroncodilatador < 80% y ≥ 30% del valor teórico normal
    c)FEV1/FVC postbroncodilatador < 70%
    (Postbroncodilatador se refiere a aproximadamente 15-30 minutos después de la inhalación de 400 µg de salbutamol)
    E.4Principal exclusion criteria
    1.Mujeres embarazadas o en periodo de lactancia 2.Mujeres potencialmente fértiles (MPF) A MENOS que cumplan la siguiente definición de postmenopausia O que estén utilizando uno o más de los métodos anticonceptivos. 3.Pacientes que hayan sido hospitalizados por una exacerbación de EPOC en las 6 semanas previas a la visita 1 durante el periodo entre la visita 2 y la visita 3. 4.Pacientes que precisen terapia de oxígeno a largo plazo (> 15 horas al día) para hipoxemia crónica. (Es aceptable la utilización “prn” hasta un total de 10 h en cualquier periodo de 24 h) 5.Pacientes que hayan presentado infección del tracto respiratorio durante las 6 semanas previas a la visita 2. 6.Los pacientes que desarrollen una infección del tracto respiratorio entre la visita 1 y la visita 3 deben retirarse del ensayo, pero se puede permitir volver a incluirlos en una fecha posterior 7.Pacientes con enfermedad pulmonar concomitante, tuberculosis pulmonar (a menos que esté confirmado por radiografía de tórax que ya no es activa) o bronquiectasias clínicamente significativas.8.Pacientes con una historia (hasta e incluyendo la visita 3) de asma indicada por (pero no limitada a: a)Recuento de eosinófilos en sangre > 400/mm3.
    b)Inicio de síntomas respiratorios antes de los 40 años de edad. 9.Pacientes con diabetes Tipo I o diabetes Tipo II no controladas incluyendo pacientes con antecedentes de concentraciones de glucosa en sangre que estén fuera del rango de normalidad con regularidad o con HbA1c > 8,0% de la Hb total determinada en la visita 2. 10.Pacientes que a criterio del investigador o del personal de Novartis responsable, tengan una anomalía de laboratorio o patología clínicamente relevante como (aunque no limitado a ello) enfermedad cardiaca isquémica inestable, arritmia (excluyendo FA estable), hipertensión no controlada, hipo- e hipertiroidismo no controlado, hipocalcemia, estado hiperadrenérgico o cualquier condición que a criterio del investigador pueda comprometer la seguridad o el cumplimiento del paciente, interferir con la evaluación, o impedir la finalización del estudio. 11.Cualquier paciente con cáncer de pulmón o antecedentes de cáncer de pulmón. 12.Cualquier paciente con cáncer activo o antecedentes de cáncer con menos de 5 años de tiempo de supervivencia libre de enfermedad. Se acepta carcinoma de células basales localizado (sin metástasis) de piel. Los pacientes con antecedentes de cáncer (excluyendo cáncer de pulmón) y 5 años o más de tiempo de supervivencia libre de enfermedad solo se pueden incluir en el estudio acordándolo con el personal de la central de Novartis caso por caso. 13.Pacientes con antecedentes de síndrome QT largo, o cuyo intervalo QTc ( medido en la visita 2 o en la visita 3 esté prolongado: > 450 ms (hombres) o > 470 ms (mujeres) tal y como es evaluado en la interpretación del ECG central (visita 2) ó en la interpretación del investigador de los ECG de predosis (visita 3). Los pacientes que no sean aptos en el ECG de selección no deben ser seleccionados de nuevo. 14.Pacientes con antecedentes de hipersensibilidad a alguno de los fármacos del estudio o a fármacos con estructura química similar 15.Pacientes que no mantengan ciclos regulares día/noche, despertarse/dormirse 16.Pacientes que hayan recibido tratamiento con otros fármacos en investigación en el momento de la inclusión, o en un plazo de 30 días o 5 semividas previas a la visita 2, lo que sea más largo.
    17.Pacientes que hayan recibido vacunas atenuadas durante los 30 días previos a la visita 2 o durante el periodo de inclusión 18.Tratamientos para EPOC y afecciones relacionadas: las siguientes medicaciones no deben ser utilizadas antes de la visita 2, durante al menos el periodo de lavado o en cualquier momento durante el estudio: •El anticolinérgico de larga duración tiotropio: 7 días.•Anticolinérgicos de corta duración: 8 horas. •Combinaciones fijas de β2 agonistas y corticosteroides inhalados: 48 horas.•Combinaciones fijas de agonistas b2 de corta duración (SABA) y anticolinérgicos inhalados: 8 horas.•LABA: 48 horas.•SABA: 6 horas.•Teofilina y otras xantinas: 1 semana. •Corticosteroides parenterales u orales: 1 mes.
    19.Tratamientos para EPOC y afecciones relacionadas: No deben utilizarse las siguientes medicaciones a menos que se hayan estabilizado:
    •Cromoglicato, nedocromilo, ketotifeno, corticosteroides inhalados o nasales y antileucotrienos al menos un mes antes de la visita 2. •Antihistamínicos al menos 5 días antes de la visita 2. 20.Otras medicaciones excluidas: •Diuréticos no ahorradores de potasio •Agentes beta-bloqueantes sistémicos. •Antiarrítmicos cardiacos de Clase Ia, Clase III, y cualquier otro fármaco con capacidad para prolongar de forma significativa el intervalo QT. •Antidepresivos tricíclicos e inhibidores de la monoamino-oxidasa.
    21.Pacientes incapaces de utilizar de forma adecuada un dispositivo inhalador de polvo seco de dosis única o múltiple o de realizar las determinaciones de la espirometría.
    E.5 End points
    E.5.1Primary end point(s)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans Information not present in EudraCT
    E.7.1.2Bioequivalence study Information not present in EudraCT
    E.7.1.3Other Information not present in EudraCT
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over Yes
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    double dummy
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA15
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days14
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days14
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation Information not present in EudraCT
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 78
    F.4.2.2In the whole clinical trial 78
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2007-12-26
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2007-11-07
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 18:50:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA